Acute Lymphocytic Leukemia with Novartis Kymriah, Pediatric

Kymriah, developed by Novartis, is a type of immunotherapy for pediatric patients with Acute Lymphocytic Leukemia (ALL). Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.

3 Result(s)

Distance

Johns Hopkins Children's Center

1800 Orleans St.
BALTIMORE, MD 21287

10 Miles

Learn more

The Children’s Hospital of Alabama

1600 7th Ave. S.
BIRMINGHAM, AL 35233

679 Miles

Learn more

Children's Hospital Los Angeles

4650 Sunset Blvd
LOS ANGELES, CA 90027

2253 Miles

Learn more

Details

Inclusions

The Bundled Rate plus Outlier Per Diems includes:

1. Those comprehensive facility services, supplies, and equipment necessary to perform the Bundled Procedure and rendered by PROVIDER 2. Those professional services necessary to perform the Bundled Procedure and rendered by a Physician 3. The treatment of any complication resulting from the performance of the Bundled Procedure 4. The Cost of the CAR T-Cell Product is included in the bundled rate. The Bundled Rate period begins on the day of the prep regime for the scheduled Accarent Procedure and covers up to 25 inpatient days in the hospital. Should the length of stay exceed 25 inpatient days, then per diem outlier payments will be applicable for each subsequent inpatient day. Covered outpatient follow-up services related to the bundled procedure beginning on the day of infusion through 60 calendar days are included in the bundled price.

Exclusions

Any chemotherapy provided / administered between after collection of stem cells and before the preparative regimen.

Candidacy

Candidacy for the bundled procedure will be determined by the Provider.

Acute Lymphocytic Leukemia with Novartis Kymriah, Pediatric

Similar Procedures